Recent Updates
Recently added Catalysts
KURA Positive Sentiment

Kura Oncology to Report First Quarter 2025 Financial Results

Thursday, April 24, 2025 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Kura Oncology, a clinical-stage biopharmaceutical company, has announced that it will report its first quarter 2025 financial results on May 1, 2025, after U.S. market close. Management will follow the announcement with a conference call and webcast at 4:30 p.m. ET to discuss the results and provide an update on corporate activities. Details on accessing the call and the company's investor relations can be found on their website.
Price reaction · baseline $6.37 (2025-04-23 close) · hit after-hours · 1 other KURA headline(s) in the window, move may be shared
day 0 close · peak
+0.9%

Market Sentiment Analysis

POSITIVE FACTORS

  • Kura Oncology is committed to precision medicines for cancer treatment.
  • The upcoming financial results could indicate positive growth for the company.
  • A corporate update will be provided, potentially revealing new developments.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+116%
120-day peak, hindsight
Typical move
5.7%
average across 9 past catalysts
Cash runway
~25 mo
Low dilution risk
Lead asset
Tipifarnib
Phase 2 · Leukemia, Myelomonocytic, Chronic

Full Press Release Details

SAN DIEGO, April 24, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced it will report first quarter 2025 financial results after the close of U.S. financial markets on Thursday, May 1, 2025. Kura’s management will host a webcast and conference call at 4:30 p.m. ET / 1:30 p.m. PT to discuss the financial results and provide a corporate update.
The live call may be accessed by dialing (800) 245-3047 for domestic callers and (203) 518-9765 for international callers and entering the conference ID: KURAQ1. A live webcast and archived replay of the event will be available here or online from the investor relations section of the company website at www.kuraoncology.com.
patti.bank@icrhealthcare.com
Alexandra Weingarten

Frequently Asked Questions

When will Kura Oncology announce Q1 2025 financial results?

Kura Oncology will report its Q1 2025 financial results on May 1, 2025.

What time is the Kura Oncology conference call?

The conference call is scheduled for 4:30 p.m. ET on May 1, 2025.

How can I access the Kura Oncology conference call?

Dial (800) 245-3047 for domestic or (203) 518-9765 for international access.

Where can I find the webcast of the Kura Oncology event?

The webcast will be available on Kura's investor relations webpage.

Who should I contact for more information about Kura Oncology?

For inquiries, contact Alexandra Weingarten at alexandra@kuraoncology.com.

ShareAdd on Google
Tags: KURA Viatris Investor Conferences Healthcare Kura Oncology Q1 2025 financial results cancer treatment biopharmaceutical
Last updated: Apr 24, 2025

Biotech snapshot

Cash runway
$519M liquidity · $21M/mo burn
~25 mo
Low dilution risk
Lead asset
TipifarnibPhase 2
Leukemia, Myelomonocytic, Chronic →

Catalyst track record

+116%
best trade around KURA's most recent catalyst

Peak hindsight return over a 120-day window, across 9 tracked FDA/PDUFA catalysts for KURA.

See every catalyst's timing & PoA →